 |
 |
|
Boehringer Ingelheim (BI), headquartered in Ingelheim, Germany, currently has almost 38,400 employees and 137 affiliated companies spread around the globe. Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Research and Development has been the foundation of Boehringer Ingelheim’s success and continues to be the major driver of innovative, new medicines. BI recognises the unique opportunities and challenges that medical needs and the health environment present. Boehringer Ingelheim has consequently committed itself to discovering, profiling and developing new products of high therapeutic value for patients and healthcare systems. Correspondingly, our Human Pharmaceuticals business has developed very dynamically in 2006. Net sales rose by 11 % to EUR million 10,200 compared with 2005, primarily due to innovative patented medications. The successful growth reinforces the patient-orientated approach of continuing intensive research into diseases and the development of new drugs and therapies that represent major therapeutic advances for patients. Boehringer Ingelheim has been at the forefront of research and development in the cardiovascular disease area for decades, establishing its market presence in the treatment of thromboembolic diseases as well as hypertension and consequential diseases. Our research programmes benefit from close interaction with research scientists in our other drug discovery units. Targeting related human diseases, such as metabolic and immunological/ inflammatory disorders, will undoubtedly increase the opportunities for developing novel, innovative therapeutic agents in the fight against cardiovascular disease. Main products from Boehringer Ingelheim for stroke therapy and prevention include Actilyse ® (alteplase), the only approved therapy for thrombolytic treatment in acute ischaemic stroke, and Aggrenox®, Asasantin®Retard (dipyridamole/ASA, which is indicated to reduce the risk of stroke in patients who have had transient ischaemia of the brain or completed ischaemic stroke due to thrombosis.
Role in ProjectBoehringer Ingelheim will be involved iin the Clinical Trial Platform. Here they will contribute their industrial expertise on issues of translational research and help choose promising candidates for ESN clinical trials. Project StaffProfessor Wolfgang Eisert, MD, PhD: Physician and physicist. Head of Post Development R&D for Boehringer Ingelheim and Professor of Biophysics at the University of Hannover.
|
